Category | Characteristic | Number of utility measures (n = 218) | |
---|---|---|---|
Number | Percentage | ||
Disease stage | Asymptomatic | 8 | 3.7% |
 | Symptomatic | 15 | 6.9% |
 | AIDS | 56 | 25.7% |
 | Not reported/Combined* | 139 | 63.8% |
Measures | EQ-5D-3L | 53 | 24.3% |
 | EQ-5D-5L | 3 | 1.4% |
 | HUI2 | 1 | 0.5% |
 | HUI3 | 20 | 9.2% |
 | 15 D | 2 | 0.9% |
 | SF-6D | 7 | 3.2% |
 | SG | 15 | 6.9% |
 | TTO | 17 | 7.8% |
 | VAS | 100 | 45.9% |
Settings | Developed countries | 168 | 77.1% |
 | Developing countries | 50 | 22.9% |
Study design | Cross-sectional | 119 | 54.6% |
 | Longitudinal | 99 | 45.4% |